



**Canadian Arthritis Network  
International Partnership Initiative**

**International Research & Training Program  
LABORATORY/CLINIC PROFILE**

**Contact information of the principal investigator**

<b>Name:</b>	Dafna Gladman
<b>Dept and Institution:</b>	Toronto Western Research Insitutue
<b>Complete mailing address:</b>	Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst St. 1E-410B, Toronto, Ontario, M5T 2S8
<b>Phone:</b>	416-603-5753
<b>Email:</b>	dafna.gladman@utoronto.ca

**Please indicate if you are member or affiliate of one or more of the following International Partnership Initiative organizations:**

- AO Foundation – Biotechnology Advisory Board, Switzerland
- Arthritis Foundation, USA
- Arthritis Research Campaign, UK
- X Canadian Arthritis Network, Canada
- Japan Society for the Promotion of Science, Japan
- Nuffield Foundation Oliver Bird Rheumatism Program, UK

**International Research & Training Program Opportunity**

**Please indicate which of the following international opportunities would be available at your laboratory/clinic.**

- X Training Elective Rotation *assuming there is funding for the individual*
- X Research Mini-sabbatical *assuming there is funding for the individual*
- Industry Training Rotation



**The International Research & Training Program will be available for trainee elective rotations and investigator mini-sabbaticals that commence on or before March 31, 2009. If you have any preferences regarding the dates when you can host an international trainee or investigator, please indicate this below.**

<b>Visit Length</b> (please indicate start and end dates if known):	
---	--

**Please provide ten key words and a brief description of the research currently being conducted in your laboratory/clinic, including descriptions of any specialized equipment, methods or technologies employed at your facility.**

**10 key words**

<ol style="list-style-type: none"><li>1. Genetic studies in Rheumatic diseases.</li><li>2. Biomarkers in psoriatic arthritis</li><li>3.</li><li>4.</li><li>5.</li><li>6.</li><li>7.</li><li>8.</li><li>9.</li><li>10.</li></ol>
---

**Brief description** (up to ½ page)

<p>Our lab concentrates on the genetics of psoriasis and psoriatic arthritis, systemic lupus erythematosus and scleroderma. We concentrate on HLA and KIR polymorphisms and their role in susceptibility and disease expression. Studies include molecular techniques- DNA isolation, PCR, SSP, SSOP.</p> <p>We are also developing studies in biomarkers for damage in psoriatic arthritis. These are primarily ELISA based methods.</p>
---

**Key publications** (maximum 5 publications)

<p>Gladman DD, Farewell, VT, Rahman P, Schentag CT, Pellet F, Ng CM, Wade JA. HLA-DRB1*04 alleles in psoriatic arthritis (PsA): comparison with rheumatoid arthritis and healthy controls. Human Immunology 2001;62:1239-1244.</p>
--



CANADIAN LE RÉSEAU  
ARTHRITIS CANADIEN  
NETWORK DE L'ARTHRITE

Martin MP, Nelson G, Lee J-H, Pellett F, Gao X, Klitz W, Wade J, Wilson M, Trowsdale J, Gladman D, Carrington M. Susceptibility to Psoriatic Arthritis: influence of activating Killer Immunoglobulin-like Receptor genes in the absence of their corresponding HLA ligands. *J Immunology* 2002; 169: 2818-2822.

Gladman DD, Farewell VT, Pellett F, Schentag C, Rahman P. HLA is a candidate region for psoriatic arthritis: Evidence for excessive HLA sharing in sibling pairs. *Human Immunol* 2003; 64: 887-889.

Nelson GW, Martin MP, Gladman D, Wade J, Trowsdale J, Carrington M. Heterozygote Advantage in Autoimmune Disease: Hierarchy of Protection/Susceptibility Conferred by HLA and KIR Combinations in Psoriatic Arthritis. *J Immunol* 2004; 173: 4273-4276.

Gladman DD, Kung TN, Siannis F, Pellett F, Farewell VT, Lee P. HLA Markers for Susceptibility and Expression in Scleroderma. *J Rheumatol* 2005; 32: 1481-1487.